C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
C4 Therapeutics, Inc.NASDAQ: CCCC
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 19.5% from a year ago
Cash & equivalents stood at $61.27M at the end of Q1 FY2026, up 19.5% from a year earlier and down 17.9% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.
Context
- Cash & equivalents amounted to 18.6% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +19.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 74.6M USD
- Year-over-year change
- +34.4%
- 4-year CAGR
- -0.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.6M | +34.4% |
| FY2024 | 2024-12-31 | 55.5M | -56.2% |
| FY2023 | 2023-12-31 | 126.59M | +325.5% |
| FY2022 | 2022-12-31 | 29.75M | -60.9% |
| FY2021 | 2021-12-31 | 76.12M | — |
Cash & Equivalents vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +19.5% is the 4th highest of 9, against a peer median of +3.1%.
- Cash & equivalents amounts to 18.6% of total assets for CCCC, versus a peer median of 32.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 78.53M CHF | -3.5% | -2.0% | 89.9% | |
| Mar 2026 | $71.32M USD | +58.2% | +112.3% | 36.8% | |
| Mar 2026 | $61.27M USD | +19.5% | +35.9% | 18.6% | |
| Mar 2026 | $42.15M USD | -3.4% | -30.7% | 27.0% | |
| Mar 2026 | $37M USD | +102.0% | -23.6% | 28.6% | |
| Mar 2026 | $29.05M USD | +166.7% | -8.6% | 9.9% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $28.2M USD | -9.1% | -16.6% | 69.8% |
| Mar 2026 | $27.59M USD | +9.6% | -40.7% | 46.0% | |
| Mar 2026 | $4.75M USD | -59.3% | -16.4% | 6.8% | |
| Peer median (excluding CCCC) | — | +3.1% | -16.5% | 32.7% | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76.12M | 29.75M | 126.59M | 55.5M | 74.6M |
| Short-term Investments | 233.16M | 246.4M | 127.09M | 189.41M | 173.93M |
| Net Receivables | 5.72M | 1.47M | 11.8M | 3.1M | 2.4M |
| Inventory | 0 | (60.96M) | 0 | 0 | 0 |
| Other Current Assets | 0 | 70.89M | 5.71M | 9.76M | 7.17M |
| Total Current Assets | 325.69M | 287.56M | 271.19M | 257.77M | 258.11M |
| Property, Plant & Equipment (Net) | 35.05M | 77.52M | 71.09M | 63.38M | 45.28M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 142.2M | 60.96M | 28.01M | 22.36M | 48.56M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.82M | 4.81M | 6.17M | 6.1M | 7.13M |
| Total Non-current Assets | 181.08M | 143.28M | 105.26M | 91.84M | 100.97M |
| Total Assets | 506.77M | 430.84M | 376.45M | 349.6M | 359.08M |
| Account Payables | 4.51M | 1.17M | 1.45M | 1.33M | 858K |
| Short-term Debt | 0 | 2.29M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 31.8M | 16.62M | 15.47M | 18.71M | 12.49M |
| Other Current Liabilities | 5.5M | 3.11M | 9.39M | 9.3M | 10.06M |
| Total Current Liabilities | 51.25M | 44.55M | 42.77M | 45.18M | 33.03M |
| Long-term Debt | 10.77M | 9.2M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 24.37M | 16.9M | 21.81M | 28.46M | 15.84M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 65.91M | 97.06M | 87.57M | 88.44M | 69.46M |
| Total Liabilities | 117.16M | 141.61M | 130.34M | 133.62M | 102.49M |
| Common Stock | 5K | 5K | 6K | 7K | 9K |
| Retained Earnings | (267.72M) | (395.89M) | (528.38M) | (633.7M) | (738.69M) |
| Accumulated OCI | (775K) | (4.14M) | (127K) | 53K | 50K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 389.61M | 289.23M | 246.11M | 215.99M | 256.59M |
| Total Debt | 42.88M | 87.15M | 70.98M | 65.76M | 59.98M |
| Net Debt | (33.25M) | 57.4M | (55.61M) | 10.26M | (14.62M) |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.